Asthma and chronic obstructive pulmonary disease (COPD) are the two most prevalent obstructive diseases of the lung. Although asthma and COPD differ in many ways some properties of each disease co-exist in some patients, particularly in patients with advanced age which recently brought up the term; Asthma-COPD Overlap Syndrome (ACOS). In addition to the fact that clinical trials deliberately exclude the patients in this group, the diagnostic criteria of ACOS are not well established. Both of these factors contribute to paucity of evidence based clinical information about ACOS. In this article my aim is to provide brief information about the history, description, clinical properties and treatment of this disease.
Introduction
Asthma and COPD are two highly prevalent forms of obstructive lung diseases, which lead to significant utilization of the healthcare systems worldwide. The hypothesis which proposes asthma and COPD to use common pathogenic mechanisms is referred as the ''Dutch Hypothesis'' and was first introduced in 1960 by N. G. M Orie and H. J. Sluiter in a multidisciplinary symposium in Groningen where scientists noted that clinical expressions of the disease are determined by endogenous (i.e. genetic factors, age, sex) and exogenous (i.e. environmental such as allergens, smoking, viruses) factors. In the following years opinions for and against this hypothesis were expressed and a ''British Theory'' was formed which states asthma and COPD are two distinct entities with different pathogenesis [1] .
The guidelines that direct our clinical practice have been highlighting the importance of correctly identifying these two diseases in order to treat and manage properly.
Definition and diagnosis of ACOS
Of these two diseases which are characterized by chronic airway inflammation, asthma is known to have a usually reversible inflammatory process which is dominated by Th2 cytokines, CD4+ lymphocytes or eosinophils and typically responds well to inhaled corticosteroids (ICS). Symptoms and signs are intermittent and may sometimes remit completely. However, in COPD inflammation is mainly mediated by Th1 cytokines with abundant CD8+ lymphocytes or neutrophils, signs and symptoms related to airway obstruction are progressive. In our daily practice we frequently observe patients with signs and symptoms of each disease which brought up the term 'ACOS' first time in 2007 in the Canadian Thoracic Society COPD guideline where it was recommended to treat COPD patients with prominent asthma component differently by adding ICS earlier in the course of treatment [2] . During recent years attention devoted to ACOS increased substantially and descriptions regarding ACOS were introduced both from asthma and COPD perspectives. ACOS diagnostic criteria (Table I) defined by Spanish experts in 2012 was later on incorporated into their consensus statement on ACOS and COPD Spanish guideline (GesEPOC) [3, 4] . Meanwhile some other European countries' guidelines mentioned similar ACOS criteria as well [5] . Many of these included variables, which are neither used in daily practice nor available in many centers and mainly based on expert opinions. Many epidemiologic studies suggested the main feature of ACOS should be diagnosis of asthma before the age of 40 in a patient with COPD however this suggestion did not gain traction thus not widely accepted [6] . (Tables II and III) . It is suggested to consider either asthma or COPD if three or more of the disease properties listed in Table III are present or to consider the diagnosis of ACOS if patients possess similar numbers of properties of asthma or COPD [7, 8] .
Furthermore, besides patients' history, physical examination and imaging studies findings it is suggested to use pulmonary function testing parameters to support the diagnosis. Pulmonary function testing parameters in asthma, COPD and ACOS are listed in Table IV [7, 8] .
In the light of the aforementioned knowledge ACOS is practically defined as COPD patients with high reversibility and/or asthma patients with advanced age who do not exhibit completely reversible airway obstruction [9] . [6] . A study from Barcelona, Spain reported prevalence of ACOS as 15.9% [5] . Another study by Soriano et al. noted that ACOS prevalence increases with age. It is 10% under 50 years olds however over 50% in patients who are over 50 years old [11] . Menezes and Hardin reported higher mean age in ACOS patients [12, 13] . Increase of prevalence with aging is thought to be related to the development of persistent airway obstruction due to inadequate treatment or ongoing insults such as smoking [14, 15] . A study by Kiljander et al. revealed ACOS prevalence as 27.4% in asthma patients who have a history of smoking. Smoking 20 pack years and age over 60 years were best predictors of ACOS in the study population and these risk factors together increase ACOS risk 6 fold (p: 0.001) [16] . The reason suggested to explain high ACOS prevalence is that asthma and airway hyperresponsiveness to be among the COPD risk factors. Lange et al. identified that deterioration of pulmonary functions is more rapid in asthma patients with even more prominence in smokers [17] . Another study revealed that 16% of asthma patients developed irreversible airway obstruction over a follow up period of 26 years [15] .
Clinical properties
Although studies on ACOS are increasing in number, information regarding clinical properties of the disease is limited.
Brzostek and Kokot's study from Poland reported 68% of patients complained of dyspnea on exertion, 63% had wheezing and paroxysmal nocturnal dyspnea and 72% had chronic productive cough [18] .
EPI-SCAN study of Miravitlles et al. revealed that when compared to COPD patients, ACOS patients had more dyspnea (p<0.001) and wheezing (92.5% vs 58.2%, p<0.001) but there were no differences between these two groups in terms of cough and sputum production. 6-minute walking test results between two groups were not different either [6] .
On the contrary, Menezes et al. described ACOS patients as the patient group who complained of cough and sputum production most frequently (p<0.001). This study revealed dyspnea symptom is more frequent in asthma patients whereas in terms of wheezing, asthma and ACOS patients have similar frequency, which is significantly more than COPD patients [12] .
de Marco et al. reported that when compared to COPD patients, ACOS patients had higher modified Medical Research Council (mMRC) scores, had more dyspnea, cough, sputum production and wheezing. Furthermore, ACOS patients had more frequent symptoms, more prominent physical impairment and higher number of hospital admissions [10] . Another population based cohort study of de Marco with a different group of investigators revealed when compared to asthma and COPD patients ACOS patients had worse basal pulmonary functions and their decline in FEV1 and FVC was similar to asthma patients but less than COPD patients. Additionally, respiratory problems necessitating emergency or hospital admissions were found to be twice as often in ACOS patients than COPD and asthma patients [19] . Two studies, which investigated pulmonary function parameters, revealed worse results in ACOS patients [6, 12] whereas Kauppi et al. and Fabbri et al. reported better parameters in ACOS patients [20, 21] . However, it should be noted that in none of these studies these differences reached statistical significance. [6, 12, 13] .
Serious exacerbations necessitating inpatient care are found to be more frequent in ACOS patients when compared to patients with COPD [10, 12, 13] .
A study performed in South Korea revealed more significant airway obstruction (i.e. low FEV1/FVC and low FEV1% predicted), more frequent hospital admissions due to respiratory problems and higher mortality rates [22] .
On the contrary, there are conflicting reports as well. A study from Australia concluded that when compared to ACOS patients COPD patients have worse prognosis, worse physical performances and more prominent decline in pulmonary functions. Additionally, COPD patients had higher rates of mortality than asthma and ACOS patients [23] .
Another report from Japan stated COPD patients had higher rates of mortality when compared to asthma and ACOS patients. Also, length of hospital stay, intensive care unit stay and duration of mechanical ventilation were longer in COPD patients [24] . CHAIN study, which was performed in Spain on a cohort of COPD patients, ACOS patients were found to have better 1-year survival rates with no significant difference in terms of exacerbation frequency [25] .
Inflammation and Biomarkers
Data regarding ACOS patients and systemic inflammation are pretty limited. Available knowledge is widely extrapolated from previous asthma and COPD studies. In contrast to the eosinophilic inflammation, which is commonly observed in asthma patients, a non-eosinophilic asthma group is identified with predominant neutrophilic inflammation whose steroid response is poor. Meanwhile it is revealed that asthma patients who had persistent airway obstruction mainly suffered from neutrophilic inflammation [26] .
Similarly, in COPD patients who are mainly affected by neutrophilic inflammation some patients have higher numbers of eosinophils in serum and sputum samples. These patients respond well to ICS, particularly who have high numbers of eosinophils in induced sputum [27] .
According to the data we can reach to the conclusion that inflammation in asthma and COPD have different properties and some patients carry similarities to each of the groups which support the diagnosis of ACOS [28] .
In 2014 Chinese investigators studied systemic inflammation in ACOS patients and checked their C-reactive protein (CRP) and interleukin-6 (IL-6) levels to compare with the available data from COPD and asthma patients, which are readily available. Study revealed that CRP and IL-6 levels in ACOS patients were higher than asthma patients and similar to COPD patients suggesting that ongoing systemic inflammation in ACOS patients is as worse as COPD patients [29] .
Treatment
Studies regarding obstructive lung diseases generally exclude asthma patients when investigating COPD treatment options and the opposite is true as well. Therefore, our knowledge on ACOS treatment generally relies on treatment strategies mentioned in asthma and COPD guidelines. Treatment trials performed solely on ACOS patients are pretty limited. The aims of ACOS treatment are controlling the symptoms and decreasing the impairment while eliminating the risks of pulmonary function deterioration, exacerbations and side effects of medications. While main reasons of morbidity in ACOS are cough, sputum production, wheezing, dyspnea on exertion, physical deconditioning and medication side effects, mortality is primarily related to exacerbations resulting in respiratory failure. Main principles of treatment are achieving symptom control cost-effectively, decreasing the number of exacerbations without any major side effects, improving quantifiable functional parameters and improving quality of life [30] .
Canadian Thoracic Society guideline published in 2007 contains information regarding ACOS patients and recommends long acting beta agonists (LABA) and long acting muscarinic receptor antagonists (LAMA) as primary choice of treatment while considering ICS treatment earlier in the course of patients with prominent asthma component. Meanwhile it is recommended to set different goals of treatment when compared to asthma and COPD patients with particular emphasis on patient education and self management plans [2] .
Czech Pneumological and Phthisiological Society's COPD guideline recommends ICS + LABA combination as first line of treatment with proven efficacy while recommending ICS + LABA + LAMA combination as an alternative. Lastly, adjunct anti-leucotriene treatments are recommended as complementary [31] .
A consensus statement from Spain in 2012 recommends ICS early in the course of treatment of every patient to suppress inflammation and using symptoms, pulmonary functions and/or sputum eosinophilia for titrating the dose of ICS. Due to the natural properties of COPD, it is recommended to add long acting bronchodilators to ICS and even consider triple therapy of ICS, LABA and LAMA if symptom control is not achieved. Even though there are conflicting statements in the consensus, early discontinuation of ICS is not recommended since this may trigger exacerbations [3] .
Spanish COPD guideline published later in 2014 includes a section dedicated to ACOS patients' management where addition of theophylline to treatment in advanced cases and a phosphodiesterase inhibitor roflumilast in patients with Kocakaya Asthma COPD overlap syndrome (ACOS) Marmara Medical Journal 2016; 29 (Special issue 2): 3-9 chronic bronchitis phenotype is recommended [4] .
GINA and GOLD guidelines include joint recommendations on ACOS treatment which include ICS + LABA or ICS + LAMA or ICS + LABA + LAMA combinations. Additionally, they explicitly express which patients should be referred to experienced centers or drug trials. Patients who have persistent symptoms despite treatment, who have exacerbations, whose diagnosis is uncertain, who have additional symptoms such as hemoptysis, weight loss, night sweats, fever and bronchiectasis signs, who have comorbidities should be referred to more experienced centers. Meanwhile all patients should receive treatment and recommendations about their modifiable risk factors including smoking cessation, management of comorbidities, non-pharmacological treatments such as physical activities, pulmonary rehabilitation and vaccination and proper self management strategies and regular follow-up [7, 8] .
Two case series comprising of 10 and 3 ACOS patients reported good response to omalizumab treatment while mentioning the necessity of further studies [32, 33] .
Conclusion
ACOS should be kept in mind in patients who have prior diagnosis of asthma or COPD while possessing properties of each disease. To establish internationally accepted diagnostic criteria and determine treatment strategies, more studies including this specific group of patients are necessary. Our current knowledge relies on applying the proper treatment recommended by asthma and COPD guidelines according to the clinical properties of patients. If there is doubt about diagnosis or treatment, patients should be referred to experienced centers.
